Ipamorelin Pharmacokinetics
Ipamorelin half-life, absorption, routes of administration, and clearance.
Rapid Absorption and GH Pulse Kinetics
Following subcutaneous administration, ipamorelin produces a discrete GH pulse that mimics the amplitude and duration of endogenous GH secretory episodes. • Subcutaneous Tmax is 15-30 minutes, with peak plasma ipamorelin concentrations followed by a terminal elimination half-life of approximately 2 hours. • GH release begins within 10 minutes of administration, peaks at 30-40 minutes, and returns to baseline by approximately 3 hours — producing a single, clean GH pulse per dose. • No accumulation occurs with repeated dosing. Each injection produces an independent GH secretory episode, preserving the pulsatile pattern that maintains GH receptor sensitivity.
Physicochemical and PK profile
- Molecular Formula
- C38H49N9O5
- Molecular Weight
- 711.85 g/mol
- CAS Number
- 170851-70-4
- Half-Life
- Approximately 2 hours
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Solubility
- Soluble in water and bacteriostatic water
- Storage
- Store lyophilized peptide at -20°C. Reconstituted solution at 2-8°C.
References
- Ipamorelin, the first selective growth hormone secretagogue · Raun K, et al. · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. · Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H · 1999
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. · Semenistaya E, Zvereva I, Thomas A et al. · 2015
- Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66. · Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM · 2001
- A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. · Timms M, Hall N, Levina V et al. · 2014
- Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a ... · Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C · 2012
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231. · Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E · 2007